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African trypanosomiasis caused by Trypanosoma bru-
cei gambiense has not been reported in Italy. We report 2
cases diagnosed in the summer of 2004. Theses cases
suggest an increased risk for expatriates working in try-
panosomiasis-endemic countries. Travel medicine clinics
should be increasingly aware of this potentially fatal
disease.
H
uman African trypanosomiasis (HAT), also known as
sleeping sickness, is caused by a flagellated try-
panosome protozoan and transmitted by Glossina (tsetse)
flies. It is classified into 3 subspecies: Trypanosoma brucei
gambiense, T. brucei rhodesiense, and T. brucei brucei (the
third subspecies is not pathogenic to humans). These sub-
species cannot be distinguished morphologically. T. b.
gambiense, which is found in western and central Africa,
causes chronic disease, while T. b. rhodesiense, which is
found in eastern and southern Africa, causes acute severe
disease. The epidemiology of these subspecies also differs
and follows distribution of their main vectors, Glossina
palpalis and G. morsitans, respectively. G. palpalis prefers
areas of vegetation near rivers and cultivated fields, and G.
morsitans feeds on wild animals in savannah areas, far
from human settlements.
Trypanosomiasis rhodesiense is a zoonosis, and
humans visiting affected areas (usually for hunting or
tourism) are accidental hosts. Humans are the only mean-
ingful reservoir of T. b. gambiense. Untreated infections
may persist for years. This disease is highly prevalent in
Africa;  ≈500,000 people are infected in 36 countries
because of poor health systems in regions of civil and mil-
itary turmoil (1). Despite its sporadic occurrence among
travelers, T. b. rhodesiense has been reported more often in
European (2) and American tourists (3) than T. b. gambi-
ense because T. b. rhodesiense is present in areas not visit-
ed by expatriates. We report 2 cases of imported
trypanosomiasis gambiense in Italy during the summer of
2004.
Patient 1 
On July 2004, a previously healthy 44-year-old man
who lived in Gabon was admitted to the outpatient clinic
of the university hospital in Udine, Italy, with a 6-month
history of recurrent fever, headache, fatigue, weight loss,
leg paresthesias, gait difficulties, and daytime somnolence.
He had been living in Libreville, Gabon, since 1961, made
yearly visits to Italy, and had never visited other African
countries. He reported frequent tsetse fly bites while sail-
ing on the Como River or walking in the forests in Gabon.
He recalled several febrile episodes that had been pre-
sumptively treated as malaria; the last occurred in
February 2004. The fever pattern then changed and
became recurrent. The patient also had headaches and
cutaneous hyperesthesia in the lower extremities. He sub-
sequently had bilateral peripheral edema of the leg and
progressive weakness, reversal of his sleep pattern with
daytime somnolence and insomnia at night, loss of
appetite, and a marked weight loss (20 kg). One month
before admission to the hospital, he was examined in an
emergency room and by a general practitioner, but a diag-
nosis was not made. Laboratory findings at that time were
an erythrocyte sedimentation rate (ESR) of 122 mm/h and
hypergammaglobulinemia (4.5 g/dL).
Upon examination, he was oriented but irritable and
apyretic. He had a blood pressure of 110/70 mm Hg and a
pulse rate of 104/min. Enlarged lymph nodes were found
in the axillae, groin, supraclavicular region, and posterior
neck triangle. The liver and spleen were enlarged (spleen
diameter 20 cm by ultrasound). Neurologic examination
showed walking ataxia, decreased sensitivity to light touch
in both legs, and no deep tendon reflexes. Laboratory tests
showed pancytopenia, an increased ESR, and hypergam-
maglobulinemia with increased levels of immunoglobulin
M (IgM) (Table). Giemsa-stained blood films showed try-
pomastigotes. Lumbar puncture showed clear cere-
brospinal fluid (CSF) with increased leukocyte counts,
protein and IgM levels, and a low glucose level (Table).
Trypanosomes were also found in the CSF (Figure 1). An
indirect hemagglutination (IHA) test result was positive
for T. brucei (titer 1:64). Second-stage sleeping sickness
(stage 2 HAT) was diagnosed, but treatment with eflor-
nithine (obtained from the World Health Organization
[WHO]) could not be initiated until 9 days after the diag-
nosis because of getting medication through customs. In
this 9-day period, daily peripheral blood smears were neg-
ative, except on day 5. The patient was then given a stan-
dard dose of eflornithine (100 mg/kg intravenously 4× /day
for 14 days), and his condition improved rapidly, lym-
phadenopathy resolved, and neurologic status normalized
within 2 weeks. Lumbar puncture on day 14 of treatment
did not show any trypanosomes, and all CSF parameters
improved. Repeat peripheral blood smears were also
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still healthy. He was advised to remain in Italy for further
follow-up, but he went back to Gabon and has not provid-
ed any subsequent medical information.
Patient 2
A 54-year-old woman was admitted to the Centre for
Tropical Diseases of Sacro Cuore Hospital of Negrar in
Verona, Italy, in late September 2004 with a 3-month his-
tory of recurrent fever, headache, insomnia, and increased
fatigue. She had lived for 30 years in the Central African
Republic and had not visited any other African countries
during that time. At admission, she was afebrile, and phys-
ical examination showed diffuse cutaneous hyperesthesia
and splenomegaly (main spleen diameter 19.5 cm by ultra-
sound). Blood cell counts and biochemical tests showed
anemia (hemoglobin level 8.3 g/dL) and leukopenia
(leukocyte count 2,700/µL). A quantitative buffy coat test
result for malaria was negative, and she was discharged. 
Three days later she returned with a fever. A quantita-
tive buffy coat test result was negative for malaria, but this
test showed viable trypomastigotes. They were also found
in peripheral blood smears (Figure 2). Serologic results for
T. brucei (IHA test) were positive (titer 1:128). Other rele-
vant laboratory findings are shown in the Table. Results of
CSF examination were normal. Since we could not treat
this patient with eflornithine (WHO provides this drug
only for stage 2 HAT), intramuscular pentamidine was
administered at the dose of 4 mg/kg for 10 days. Tests to
detect trypanosomes in blood were conducted daily for 8
days after treatment was initiated, but no trypomastigotes
were found. Her clinical course was uneventful, except for
a sterile abscess at the injection site. All laboratory find-
ings improved markedly. She was afebrile and was dis-
charged on day 25 in good condition, although she still had
insomnia and headaches.
In February 2005, she returned for a follow-up exami-
nation. The headaches and insomnia continued (she did not
sleep >2 hours per night). Laboratory findings, including
serum IgM levels, were within normal ranges. Total pro-
tein levels in CSF increased to 570 mg/dL, but cells in CSF
were within normal ranges. Based on these findings, treat-
ment with intravenous eflornithine (100 mg/kg 4×/day for
14 days) was initiated. The patient had generalized tremors
(without fever) during the third infusion (no electroen-
cephalographic signs of convulsions), but subsequent find-
ings were uneventful. She was discharged after completion
of treatment. At a follow-up visit in April 2005, she report-
ed a nearly normal sleeping pattern.
Conclusions 
Eighty-four imported cases of trypanosomiasis caused
by T. b. gambiense were reported in Europe before 1963.
From 1966 to 1979, 12 cases were reported in France,
which reported the most cases in Europe (4). During this
period, incidence in trypanosomiasis-endemic countries
decreased after intensive control activities. Eight imported
cases of infection with T. b. gambiense in persons from
Europe have been reported since 1985 (4–11), and 2 addi-
tional cases were recorded in France by the Centre
National de Référence de l’Epidémiologie du Paludisme
d’Importation et Autochtone (F. Legros, pers. comm.). To
our knowledge, T. b. gambiense infection has not been
reported in Italy (C. Mauro, Ministry of Health, pers.
comm.).
Both patients denied visiting African countries where T.
b. rhodesiense was present. A sporadic case of infection
with T. b. gambiense in an Italian expatriate in Zaire (now
the Democratic Republic of Congo) was reported in
Belgium in 1996 (12). The simultaneous occurrence of
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Figure 1. Trypomastigote (arrow) in a Giemsa-stained cere-
brospinal fluid smear of patient 1 (original magnification ×1,000).2 cases in Italy suggests an increased risk for infection
with T. b. gambiense in expatriates working in disease-
endemic areas. This increased risk is not surprising if one
considers the increased incidence of this infection in
African countries (1).
In countries not endemic for this infection, diagnosis of
imported cases of infection with T. b. gambiense is chal-
lenging because of variations in clinical signs and symp-
toms and low sensitivities of diagnostic tests (13). The first
patient in our study was misdiagnosed and not treated for
several weeks because he had no fever and clinical mani-
festations were limited to neurologic symptoms. The sec-
ond patient was also initially misdiagnosed. High levels of
IgM in blood and an enlarged spleen should suggest the
possibility of trypanosomiasis (the main differential diag-
nosis is hyperreactive malarial splenomegaly). Techniques
for concentrating parasites should be used, and blood films
should be examined daily in patients with these symptoms.
Involvement of the central nervous system in trypanoso-
miasis has been confirmed by increased lymphocyte counts
(>5 cells/µL) or trypanosomes in CSF (14). However, as in
the second patient, neurologic involvement cannot be ruled
out even in those in whom CSF is normal. Better indicators
of infection in blood and CSF are needed. Leukocyte
counts >20 cells/µL in CSF and intrathecal IgM synthesis
independent of trypanosomes in CSF have been proposed
as modified criteria for diagnosis of stage 2 HAT (14,15).
Eflornithine, the preferred treatment for stage 2 HAT,
was obtained from WHO to treat 1 of the patients.
However, custom formalities in Italy, which resulted in a
delay in receiving this drug, are inappropriate for emer-
gency drug treatment. Thus, our experience with the 2
patients and recent outbreaks of infection with T. b. rhode-
siense emphasize the need for readily available trypanoci-
dal drugs.
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Figure 2.Trypomastigotes in a Giemsa-stained thin blood film of
patient 2 (original magnification ×1,000).